Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Testing more genes upfront saves lives in lung cancer. A large real-world study found that advanced NSCLC patients who received broad-based genomic sequencing (BGS) before first-line treatment lived about two months longer on average than those who got narrow biomarker testing. The findings reinforce NCCN guidelines recommending comprehensive genomic testing as the standard of care.
Testing more genes upfront saves lives in lung cancer
A new study published in the JNCCN—Journal of the National Comprehensive Cancer Network (November 2026) confirms that casting a wider genomic net before treatment begins leads to better outcomes for advanced non-small cell lung cancer (NSCLC) patients. Researchers analyzed real-world data from over 35,000 patients treated across U.S. community and academic oncology practices between 2016 and 2022.
Patients who received broad-based genomic sequencing (BGS)—testing dozens to hundreds of genes simultaneously—before starting first-line therapy lived longer and had better progression-free survival than those who received narrow, one-or-two-gene biomarker testing. The benefit likely stems from BGS identifying a wider range of actionable mutations, enabling more precise, targeted treatment matching.
By the Numbers
Why it matters: NCCN guidelines already recommend BGS for advanced/metastatic NSCLC, but access remains uneven across insurance types, providers, and locations. Researchers are calling for equitable coverage of comprehensive biomarker testing so that no patient misses out on a potentially life-extending targeted therapy simply because of where or how they receive care.
